Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia

References

• Macchiaiolo M, Gagliardi MG, Toscano A, et al. Homozygous familial hypercholesterolaemia. Lancet. 2012;379(9823):1330.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111(12):1795–1803.
   PubMed Web of Science ®Google Scholar
• Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev. 2004;25(1):49–68.
   PubMedGoogle Scholar
• Vallejo-Vaz AJ, Ray KK. Epidemiology of familial hypercholesterolaemia: community and clinical. Atherosclerosis. 2018;277:289–297.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Tremblay G, Perron P, et al. familial hypercholesterolemia in eastern quebec: A public health problem? The experience of the hyperlipidemia clinic of chicoutimi. Union Med Can. 1995;124(2):54–60.
   PubMedGoogle Scholar
• Smyth N, Ramsay M, Raal FJ. Population specific genetic heterogeneity of familial hypercholesterolemia in south africa. Curr Opin Lipidol. 2018;29(2):72–79.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Ruel I, Aljenedil S, et al. Canadian cardiovascular society position statement on familial hypercholesterolemia: update2018. Can J Cardiol. 2018;34(12):1553–1563.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of pcsk9 with evolocumab in homozygous familial hypercholesterolaemia (tesla part b): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341–350.
   PubMed Web of Science ®Google Scholar
• Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the ldlr (low-density lipoprotein receptor): implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol. 2018;38(3):592–598.
   PubMed Web of Science ®Google Scholar
• Hudgins LC, Gordon BR, Parker TS, et al. Ldl apheresis: an effective and safe treatment for refractory hypercholesterolemia. Cardiovasc Drug Rev. 2002;20(4):271–280.
   PubMed Web of Science ®Google Scholar
• Moriarty PM. Ldl-apheresis therapy. Curr Treat Options Cardiovasc Med. 2006;8(4):282–288.
   PubMedGoogle Scholar
• Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for ldl apheresis. Atherosclerosis. 2010;208(2):317–321.
   PubMed Web of Science ®Google Scholar
• Kolovou G, Vasiliadis I, Gontoras N, et al. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance. Cardiovasc Ther. 2015;33(2):71–78.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Goldberg AC, Moriarty PM. Managing the challenging homozygous familial hypercholesterolemia patient: academic insights and practical approaches for a severe dyslipidemia, a national lipid association masters summit. J Clin Lipidol. 2017;11(3):602–616.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. Angptl3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296–297.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Khoury E, et al. Safety and efficacy of evinacumab, a monoclonal antibody to angptl3, in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, proof-of-concept study. Atherosclerosis. 2016;252:e254–e255.
   Web of Science ®Google Scholar
• Gaudet D, Saheb S, Bruckert E, et al. A pilot study of mbx-8025 in the treatment of homozygous familial hypercholesterolemia (hofh). Atherosclerosis. 2016;252:e253.
   Web of Science ®Google Scholar
• Hovingh GK, Smits LP, Stefanutti C, et al. The effect of an apolipoprotein a-i-containing high-density lipoprotein-mimetic particle (cer-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the modifying orphan disease evaluation (mode) study. Am Heart J. 2015;169(5):736–742. e731.
   PubMed Web of Science ®Google Scholar
• Ajufo E, Cuchel M. Recent developments in gene therapy for homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2016;18(5):22.
   PubMed Web of Science ®Google Scholar
• Ajufo E, Rader DJ. New therapeutic approaches for familial hypercholesterolemia. Annu Rev Med. 2018;69:113–131.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483–492.
   PubMed Web of Science ®Google Scholar
• Gossios T, Zografou I, Simoulidou V, et al. Multimodal treatment of homozygous familial hypercholesterolemia. Curr Pharm Des. 2018;24(31):3616–3621.
   PubMed Web of Science ®Google Scholar
• Juxtapid (lomitapide) capsules, for oral use. Initial u.S. Approval. 2012. [cited 2018 Nov]. Available from: https://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2012/203858s000lbl.Pdf
   Google Scholar
• Clinical review(s) of lomitapide for treating patients with homozygous familial hypercholesterolemia. Fda drug approvals and databases. Washington, dc:: Fda/center for drug evaluation and research; 2012. [cited 2018 Nov]. Available from: http://www.Accessdata.Fda.Gov/drugsatfda_docs/nda/2012/203858orig1s000medr.Pdf
   Google Scholar
• Vuorio A, Tikkanen MJ, Kovanen PT. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vasc Health Risk Manag. 2014;10:263–270.
   PubMedGoogle Scholar
• Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148–156.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C. et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40–46.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years‘ treatment with lomitapide. JAMA Intern Med. 2014;174(3):443–447.
   PubMed Web of Science ®Google Scholar
• Alonso R, Mata P, Alonso YGM, et al. homozygous familial hypercholesterolemia. First case in spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein b. Med Clin (Barc). 2015;145(5):229–230.
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide. J Clin Lipidol. 2015;9(4):607–617.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Morozzi C, Di Giacomo S, et al. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 italian patients treated in rome with lomitapide and lipoprotein apheresis. J Clin Lipidol. 2016;10(4):782–789.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Kolovou V, Papadopoulou A, et al. Mtp gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2016;23(7):878–883.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022–1032.
   PubMed Web of Science ®Google Scholar
• Berthier MT, Couture P, Houde A, et al. The c.419-420insa in the mtp gene is associated with abetalipoproteinemia among french-canadians. Mol Genet Metab. 2004;81(2):140–143.
   PubMed Web of Science ®Google Scholar
• Narcisi TM, Shoulders CC, Chester SA, et al. Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. Am J Hum Genet. 1995;57(6):1298–1310.
   PubMed Web of Science ®Google Scholar
• Rimbert A, Pichelin M, Lecointe S, et al. Identification of novel apob mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia. Atherosclerosis. 2016;250:52–56.
   PubMed Web of Science ®Google Scholar
• Magnolo L, Noto D, Cefalu AB, et al. Characterization of a mutant form of human apolipoprotein b (thr26_tyr27del) associated with familial hypobetalipoproteinemia. Biochim Biophys Acta. 2016;1861(4):371–379.
   PubMed Web of Science ®Google Scholar
• Hooper AJ, Heeks L, Robertson K, et al. Lipoprotein metabolism in apob l343v familial hypobetalipoproteinemia. J Clin Endocrinol Metab. 2015;100(11):E1484–1490.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol. 2013;24(3):246–250.
   PubMed Web of Science ®Google Scholar
• Product monograph, juxtapid, lomitapide capsules. [cited 2017 Aug]. Available from: http://www.Aegerion.Ca/collateral/documents/canada-english/final%20pristine%20monograph%20copy.Pdf
   Google Scholar
• Blom DJ, Averna MR, Meagher EA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136(3):332–335.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein b synthesis inhibitor, for lowering of ldl cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998–1006.
   PubMed Web of Science ®Google Scholar
• Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein b synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32(21):2650–2659.
   PubMed Web of Science ®Google Scholar
• Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein b synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62(23):2178–2184.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. Safety and efficacy of evinacumab, a monoclonal antibody to angptl3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies. J Clin Lipidol. 2016;10(3):715.
   Google Scholar
• Blom DJ, Fayad ZA, Kastelein JJ, et al. Investigators L: lower, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design. J Clin Lipidol. 2016;10(2):273–282.
   PubMed Web of Science ®Google Scholar
• Blom D, Averna M, Meagher E, du Toit Theron H, Sirtori C, Hegele R, Shah P, Gaudet D, Stefanutti C, Vigna G, Foulds P, et al. Long-term efficacy and safety of lomitapide for the treatment of homozygous familial hypercholesterolemia: results of the phase 3 extension trial. Circulation. 2015;132:A12450.
   Web of Science ®Google Scholar
• Kameyama N, Maruyama C, Kitagawa F, et al. Dietary intake during 56 weeks of a low-fat diet for lomitapide treatment in japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2018;26(1):72–83.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Blom DJ, Averna MR, et al. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a phase 3, single-arm, open-label trial. Atherosclerosis. 2015;240(2):408–414.
   PubMed Web of Science ®Google Scholar
• Brahm AJ, Hegele RA. Lomitapide for the treatment of hypertriglyceridemia. Expert Opin Investig Drugs. 2016;25(12):1457–1463.
   PubMed Web of Science ®Google Scholar
• Chandler CE, Wilder DE, Pettini JL, et al. Cp-346086: an mtp inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003;44(10):1887–1901.
   PubMed Web of Science ®Google Scholar
• Consortium CAD, Deloukas P, Kanoni S, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25–33.
   PubMed Web of Science ®Google Scholar
• Liu X, Men P, Wang Y, et al. Efficacy and safety of lomitapide in hypercholesterolemia. Am J Cardiovasc Drugs. 2017;17(4):299–309.
   PubMed Web of Science ®Google Scholar
• D‘Erasmo L, Cefalu AB, Noto D, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in italy. Adv Ther. 2017;34(5):1200–1210.
   PubMed Web of Science ®Google Scholar
• Raper A, Kolansky DM, Sachais BS, et al. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. J Clin Lipidol. 2015;9(1):107–112.
   PubMed Web of Science ®Google Scholar
• Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in japanese patients with homozygous familial hypercholesterolemia (hofh): results from the aegr-733-301 long-term extension study. J Atheroscler Thromb. 2019;26(4):368–377.
   Web of Science ®Google Scholar
• Yoshida H. A first-in-class drug, lomitapide, tailored to patients with homozygous familial hypercholesterolemia is just about meeting with good news to them. J Atheroscler Thromb. 2017;24(4):390–392.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Cuchel M, Ager M, et al. Target achievement and cardiovascular event rates with lomitapide in homozygous familial hypercholesterolaemia. Orphanet J Rare Dis. 2018;13(1):96.
   PubMedGoogle Scholar
• Sperlongano S, Gragnano F, Natale F, et al. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. J Cardiovasc Med (Hagerstown). 2018;19(3):83–90.
   PubMed Web of Science ®Google Scholar
• Blom D, Kastelein JJ, Larrey D, et al. Lomitapide observational worldwide evaluation registry (lower): one-year data. Circulation. 2015;132(Suppl 3):A10818.
   Google Scholar
• Fda briefing document, nda 203568. Mipomersen sodium injection 200 mg/ml. Materials for the endocrinologic and metabolic drugs advisory committee meeting, 18 october 2012. [cited 2018 Nov]. Available from: https://www.Accessdata.Fda.Gov/drugsatfda_docs/nda/2013/203568orig1s000pharmr.Pdf.
   Google Scholar
• Toth PP. Novel therapies for low-density lipoprotein cholesterol reduction. Am J Cardiol. 2016;118(6 Suppl):19A–32A.
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36(9):566–575.
   PubMed Web of Science ®Google Scholar
• Neef D, Berthold HK, Gouni-Berthold I. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Expert Rev Clin Pharmacol. 2016;9(5):655–663.
   PubMed Web of Science ®Google Scholar
• Li N, Li Q, Tian XQ, et al. Mipomersen is a promising therapy in the management of hypercholesterolemia: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2014;14(5):367–376.
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein b synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(19):2283–2292.
   PubMed Web of Science ®Google Scholar
• McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7(11):e49006.
   PubMed Web of Science ®Google Scholar
• Hashemi N, Odze RD, McGowan MP, et al. Liver histology during mipomersen therapy for severe hypercholesterolemia. J Clin Lipidol. 2014;8(6):606–611.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol. 2006;44(1):190–196.
   PubMed Web of Science ®Google Scholar
• Tarugi P, Averna M, Di Leo E, et al. Molecular diagnosis of hypobetalipoproteinemia: an enid review. Atherosclerosis. 2007;195(2):e19–27.
   PubMed Web of Science ®Google Scholar
• Yahya R, Mulder MT, Sijbrands EJ, et al. Roeters van Lennep JE: low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolemia: two lifetime journeys of lipid-lowering therapy. J Clin Lipidol. 2017;11(1):301–305.
   PubMed Web of Science ®Google Scholar
• Won JI, Zhang J, Tecson KM, et al. Balancing low-density lipoprotein cholesterol reduction and hepatotoxicity with lomitapide mesylate and mipomersen in patients with homozygous familial hypercholesterolemia. Rev Cardiovasc Med. 2017;18(1):21–28.
   PubMed Web of Science ®Google Scholar
• Brown WV, Bramlet DA, Ross JL, et al. Jcl roundtable: risk evaluation and mitigation strategy. J Clin Lipidol. 2016;10(6):1288–1296.
   PubMed Web of Science ®Google Scholar
• Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18(12):1261–1268.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Drouin-Chartier JP, Couture P. Lipid metabolism and emerging targets for lipid-lowering therapy. Can J Cardiol. 2017;33(7):872–882.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Julius U, Watts GF, et al. Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol. 2017;11(4):858–871. e853.
   PubMed Web of Science ®Google Scholar
• Juxtapid (lomitapide) capsules, risk evaluation and mitigation strategy (rems). [cited 2017 Aug]. Available from: https://www.Fda.Gov/downloads/drugs/drugsafety postmarketdrugsafetyinformationforpatients andproviders/ucm333438.Pdf
   Google Scholar
• Summary of the european public assessment report (epar) for lojuxta. European medicines agency, science medicines health. Canary wharf, london, uk: European medicines agency; 2016. [cited 2016 Dec]. Available from: http://www.Ema.Europa.Eu/docs/en_gb/document_library/epar_-_summary_for_the_public/human/002578/wc500148552.Pdf
   Google Scholar
• Assessment report of the committee for medicinal products for human use (chmp) for lojuxta. European medicines agency, science medicines health. Canary wharf, london, uk: European medicines agency; 2013. [cited 2019 Jan]. Available from: https://www.Ema.Europa.Eu/documents/assessment-report/lojuxta-epar-public-assessment-report_en.Pdf
   Google Scholar
• Cuchel M, Blom DJ, Averna MR. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atheroscler Suppl. 2014;15(2):33–45.
   PubMed Web of Science ®Google Scholar
• Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995;92(9):2419–2425.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group. N Engl J Med. 1995;333(20):1301–1307.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of angptl3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222–232.
   PubMed Web of Science ®Google Scholar
• Stein E, Bays H, Koren M, et al. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016;10(5):1212–1222.
   PubMed Web of Science ®Google Scholar
• Karalis I, Jukema JW. Hdl mimetics infusion and regression of atherosclerosis: is it still considered a valid therapeutic option? Curr Cardiol Rep. 2018;20(8):66.
   PubMed Web of Science ®Google Scholar
• Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55(24):2727–2735.
   PubMed Web of Science ®Google Scholar
• Pharmacoeconomic evaluation. Cdr submission: juxtapid™ (lomitapide), 5 mg, 10 mg and 20 mg capsules. Company: aegerion pharmaceuticals (canada) ltd. [confidential manufacturer‘s submission]. Toronto: Aegerion pharmaceuticals (canada) ltd. [2014 Jul 7.
   Google Scholar
• Kei series on patents that fail to disclose u.S. Government funding. The undisclosed rader patents for juxtapid, 19 march 2018. [last accessed Feb 2019]. Available from: https://www.Keionline.Org/wp-content/uploads/2018/03/juxtapid-failure2disclose-daniel-rader-19mar2018.Pdf
   Google Scholar
• Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5(8):497–505.
   PubMedGoogle Scholar
• Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein b and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein b. Circulation. 2006;114(16):1729–1735.
   PubMed Web of Science ®Google Scholar
• Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein b, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55(15):1611–1618.
   PubMed Web of Science ®Google Scholar
• Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein b synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413–1419.
   PubMed Web of Science ®Google Scholar
• Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-b synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057–1062.
   PubMed Web of Science ®Google Scholar